The Front Cover highlights advances in CRBN-recruiting molecular glue degraders since 2023, illustrating the shift from canonical glues to non-canonical chemotypes that expand the neosubstrate space. A glutarimide anchor binds to CRBN, while ligand-specific features shape the CRBN–ligand–neosubstrate interface. AI-enabled modeling can further accelerate the discovery of atypical MGDs. More information can be found in the Review by N.-J. Kim and co-workers (DOI: 10.1002/ejoc.202501208). Created in BioRender: Won, H.-J. (2026) https://BioRender.com/x39o4mt.
Won et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: